Zacks Research Has Pessimistic Outlook of PAHC Q3 Earnings

Phibro Animal Health Co. (NASDAQ:PAHC - Free Report) - Stock analysts at Zacks Research dropped their Q3 2025 earnings estimates for Phibro Animal Health in a research note issued on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.35 for the quarter, down from their prior forecast of $0.37. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.61 per share. Zacks Research also issued estimates for Phibro Animal Health's Q1 2026 earnings at $0.32 EPS, Q3 2026 earnings at $0.33 EPS and Q1 2027 earnings at $0.48 EPS.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.07. The firm had revenue of $273.16 million during the quarter, compared to analysts' expectations of $262.44 million. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%.

A number of other analysts have also recently commented on PAHC. Barclays increased their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an "underweight" rating in a research note on Tuesday, November 12th. StockNews.com lowered Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Bank of America lifted their price objective on shares of Phibro Animal Health from $13.00 to $15.00 and gave the stock an "underperform" rating in a research report on Friday, August 30th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Phibro Animal Health in a research note on Tuesday, September 10th. They set a "neutral" rating and a $22.00 target price for the company. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $16.50.

Phibro Animal Health Stock Up 2.2 %

Phibro Animal Health stock traded up $0.52 during mid-day trading on Monday, reaching $24.14. The company's stock had a trading volume of 193,194 shares, compared to its average volume of 158,911. The company has a market capitalization of $977.67 million, a price-to-earnings ratio of 55.21, a price-to-earnings-growth ratio of 0.61 and a beta of 0.51. Phibro Animal Health has a 12 month low of $9.49 and a 12 month high of $25.98. The business's 50 day simple moving average is $23.16 and its 200 day simple moving average is $20.03. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in shares of Phibro Animal Health by 5.7% during the third quarter. Geode Capital Management LLC now owns 507,469 shares of the company's stock valued at $11,430,000 after purchasing an additional 27,201 shares in the last quarter. Barclays PLC raised its position in Phibro Animal Health by 25.7% during the 3rd quarter. Barclays PLC now owns 143,337 shares of the company's stock worth $3,228,000 after purchasing an additional 29,271 shares during the last quarter. Zacks Investment Management bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $274,000. Virtus Investment Advisers Inc. raised its position in shares of Phibro Animal Health by 65.1% during the third quarter. Virtus Investment Advisers Inc. now owns 24,344 shares of the company's stock worth $548,000 after acquiring an additional 9,600 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in shares of Phibro Animal Health by 116.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company's stock worth $4,330,000 after acquiring an additional 103,491 shares during the period. 99.34% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director E Thomas Corcoran purchased 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 4th. The shares were bought at an average cost of $20.02 per share, with a total value of $100,100.00. Following the acquisition, the director now owns 25,000 shares of the company's stock, valued at $500,500. This trade represents a 25.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 50.07% of the company's stock.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Wednesday, November 27th will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.99%. The ex-dividend date of this dividend is Wednesday, November 27th. Phibro Animal Health's dividend payout ratio (DPR) is presently 111.63%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.